Targeted Temperature Management After In-Hospital Cardiac Arrest: An Ancillary Analysis of Targeted Temperature Management for Cardiac Arrest With Nonshockable Rhythm Trial Data.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
08 2022
Historique:
received: 04 09 2021
revised: 10 02 2022
accepted: 17 02 2022
pubmed: 24 3 2022
medline: 11 8 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

Targeted temperature management (TTM) currently is the only treatment with demonstrated efficacy in attenuating the harmful effects on the brain of ischemia-reperfusion injury after cardiac arrest. However, whether TTM is beneficial in the subset of patients with in-hospital cardiac arrest (IHCA) remains unclear. Is TTM at 33 °C associated with better neurological outcomes after IHCA in a nonshockable rhythm compared with targeted normothermia (TN; 37 °C)? We performed a post hoc analysis of data from the published Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm randomized controlled trial in 584 patients. We included the 159 patients with IHCA; 73 were randomized to 33 °C treatment and 86 were randomized to 37 °C treatment. The primary outcome was survival with a good neurologic outcome (cerebral performance category [CPC] score of 1 or 2) on day 90. Mixed multivariate adjusted logistic regression analysis was performed to determine whether survival with CPC score of 1 or 2 on day 90 was associated with type of temperature management after adjustment on baseline characteristics not balanced by randomization. Compared with TN for 48 h, hypothermia at 33 °C for 24 h was associated with a higher percentage of patients who were alive with good neurologic outcomes on day 90 (16.4% vs 5.8%; P = .03). Day 90 mortality was not significantly different between the two groups (68.5% vs 76.7%; P = .24). By mixed multivariate analysis adjusted by Cardiac Arrest Hospital Prognosis score and circulatory shock status, hypothermia was associated significantly with good day 90 neurologic outcomes (OR, 2.40 [95% CI, 1.17-13.03]; P = .03). Hypothermia at 33 °C was associated with better day 90 neurologic outcomes after IHCA in a nonshockable rhythm compared with TN. However, the limited sample size resulted in wide CIs. Further studies of patients after cardiac arrest resulting from any cause, including IHCA, are needed.

Sections du résumé

BACKGROUND
Targeted temperature management (TTM) currently is the only treatment with demonstrated efficacy in attenuating the harmful effects on the brain of ischemia-reperfusion injury after cardiac arrest. However, whether TTM is beneficial in the subset of patients with in-hospital cardiac arrest (IHCA) remains unclear.
RESEARCH QUESTION
Is TTM at 33 °C associated with better neurological outcomes after IHCA in a nonshockable rhythm compared with targeted normothermia (TN; 37 °C)?
STUDY DESIGN AND METHODS
We performed a post hoc analysis of data from the published Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm randomized controlled trial in 584 patients. We included the 159 patients with IHCA; 73 were randomized to 33 °C treatment and 86 were randomized to 37 °C treatment. The primary outcome was survival with a good neurologic outcome (cerebral performance category [CPC] score of 1 or 2) on day 90. Mixed multivariate adjusted logistic regression analysis was performed to determine whether survival with CPC score of 1 or 2 on day 90 was associated with type of temperature management after adjustment on baseline characteristics not balanced by randomization.
RESULTS
Compared with TN for 48 h, hypothermia at 33 °C for 24 h was associated with a higher percentage of patients who were alive with good neurologic outcomes on day 90 (16.4% vs 5.8%; P = .03). Day 90 mortality was not significantly different between the two groups (68.5% vs 76.7%; P = .24). By mixed multivariate analysis adjusted by Cardiac Arrest Hospital Prognosis score and circulatory shock status, hypothermia was associated significantly with good day 90 neurologic outcomes (OR, 2.40 [95% CI, 1.17-13.03]; P = .03).
INTERPRETATION
Hypothermia at 33 °C was associated with better day 90 neurologic outcomes after IHCA in a nonshockable rhythm compared with TN. However, the limited sample size resulted in wide CIs. Further studies of patients after cardiac arrest resulting from any cause, including IHCA, are needed.

Identifiants

pubmed: 35318006
pii: S0012-3692(22)00491-3
doi: 10.1016/j.chest.2022.02.056
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-366

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Alexiane Blanc (A)

Médecine Intensive Réanimation, University Hospital Center, Nantes, France.

Gwenhael Colin (G)

Medical-Surgical Intensive Care Unit, District Hospital Center, La Roche-sur-Yon, France.

Alain Cariou (A)

Paris Cardiovascular Research Center, INSERM U970, Paris, France; Medical Intensive Care Unit, Cochin University Hospital Center, Paris, France; AfterROSC Network, Cochin University Hospital Center, Paris, France.

Hamid Merdji (H)

Faculté de Médecine Université de Strasbourg (UNISTRA) and the Service de Médecine Intensive Réanimation (H. Merdji), Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France; UMR 1260, Regenerative Nano Medecine, INSERM, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Guillaume Grillet (G)

Medical Intensive Care Unit, South Brittany General Hospital Center, Lorient, France.

Patrick Girardie (P)

Médecine Intensive Réanimation, CHU Lille, and the Université de Lille, Faculté de Médicine, Lille, France.

Elisabeth Coupez (E)

Medical Intensive Care Unit, University Hospital Center, Clermond-Ferrand, France.

Pierre-François Dequin (PF)

Medical Intensive Care Unit, University Hospital Center, Tours, France; Inserm UMR 1100-Centre d'Étude des Pathologies Respiratoires, Tours University, Tours, France.

Thierry Boulain (T)

Medical Intensive Care Unit, Regional Hospital Center, Orleans, France.

Jean-Pierre Frat (JP)

Medical Intensive Care Unit, University Hospital Center, Poitiers, France; INSERM, CIC-1402, Équipe ALIVE, Poitiers, France; Faculté de Médecine et de Pharmacie de Poitiers, Université de Poitiers, Poitiers, France.

Pierre Asfar (P)

Medical Intensive Care Unit, University Hospital Center, Angers, France.

Nicolas Pichon (N)

AfterROSC Network, Cochin University Hospital Center, Paris, France; Service de Réanimation Polyvalente, University Hospital Center, Limoges, France; CIC 1435, University Hospital Center, Limoges, France.

Mickael Landais (M)

Medical-Surgical Intensive Care Unit, General Hospital Center, Le Mans, France.

Gaëtan Plantefeve (G)

Medical-Surgical Intensive Care Unit, General Hospital Center, Argenteuil, France.

Jean-Pierre Quenot (JP)

Medical Intensive Care Unit, University Hospital Center, Dijon, France.

Jean-Charles Chakarian (JC)

Medical-Surgical Intensive Care Unit, General Hospital Center, Roanne, France.

Michel Sirodot (M)

Medical-Surgical Intensive Care Unit, General Hospital Center, Annecy, France.

Stéphane Legriel (S)

AfterROSC Network, Cochin University Hospital Center, Paris, France; Medical-Surgical Intensive Care Unit, Versailles Hospital, Versailles, France.

Nicolas Massart (N)

Medical-Surgical Intensive Care Unit, General Hospital Center, Saint Brieuc, France.

Didier Thevenin (D)

Medical-Surgical Intensive Care Unit, General Hospital Center, Lens, France.

Arnaud Desachy (A)

Medical-Surgical Intensive Care Unit, General Hospital Center, Angouleme, France.

Arnaud Delahaye (A)

Medical-Surgical Intensive Care Unit, General Hospital Center, Rodez, France.

Vlad Botoc (V)

Medical-Surgical Intensive Care Unit, General Hospital Center, Saint Malo, France.

Sylvie Vimeux (S)

Medical-Surgical Intensive Care Unit, General Hospital Center, Montauban, France.

Frederic Martino (F)

Medical Intensive Care Unit, University Hospital Center, Pointe-à-Pitre, France.

Jean Reignier (J)

Médecine Intensive Réanimation, University Hospital Center, Nantes, France.

F S Taccone (FS)

Erasmus University Hospital, Free University of Brussels, Brussels, Belgium.

J B Lascarrou (JB)

Médecine Intensive Réanimation, University Hospital Center, Nantes, France; Paris Cardiovascular Research Center, INSERM U970, Paris, France; AfterROSC Network, Cochin University Hospital Center, Paris, France. Electronic address: jeanbaptiste.lascarrou@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH